HW
CRBP icon

Hancock Whitney’s Corbus Pharmaceuticals CRBP Stock Holding History

Hancock Whitney’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-565
Closed -$31K – 801
2020
Q3 		$31K Hold
565
– – ﹤0.01% 778
2020
Q2 		$142K Buy
+565
New +$114K 0.01% 732

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hancock Whitney's CRBP Position: Q4 2020 in Review

Hancock Whitney sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 565 shares — an estimated $31K sold.

Hancock Whitney first reported a position in CRBP in Q2 2020 and held it in 2 quarters. The position peaked at $142K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

  • Hancock Whitney reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Hancock Whitney sold 565 Corbus Pharmaceuticals shares in Q4 2020, an estimated $31K.
  • Hancock Whitney first reported a position in Corbus Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Hancock Whitney's Corbus Pharmaceuticals position peaked at $142K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on Hancock Whitney's 13F filing for Q4 2020, filed 9 Feb 2021.